NEW YORK--(BUSINESS WIRE)--OMRIX Biopharmaceuticals, Inc. (“OMRIX” or “the Company”) (NASDAQ: OMRI), a biopharmaceutical Company that develops and markets biosurgical and passive immunotherapy products, announced today the results of its prospective, open label, Phase I study of its novel Fibrin Patch. The results show that the Fibrin Patch appears to be safe as an adjunct to hemostasis.
The fully absorbable Fibrin Patch, developed together with ETHICON, INC., contains proprietary biologics which form an instant clot when they come in contact with blood. It is intended to rapidly manage the whole spectrum of bleeding, from mild to potentially life threatening severe bleeding.
